{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:12:23Z","timestamp":1791821543570,"version":"4.3.4"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/nrgastro.2011.97","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T11:15:49Z","timestamp":1307445349000},"page":"385-394","source":"Crossref","is-referenced-by-count":126,"title":["Gastrointestinal effects of aspirin"],"prefix":"10.1038","volume":"8","author":[{"given":"Carlos","family":"Sostres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,4]]},"reference":[{"key":"BFnrgastro201197_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","volume":"56","author":"DL Simmons","year":"2004","unstructured":"Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387\u2013437 (2004).","journal-title":"Pharmacol. Rev."},{"key":"BFnrgastro201197_CR2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","volume":"2","author":"PJ Loll","year":"1995","unstructured":"Loll, P. J., Picot, D. & Garavoto, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 2, 637\u2013643 (1995).","journal-title":"Nat. Struct. Biol."},{"key":"BFnrgastro201197_CR3","doi-asserted-by":"crossref","first-page":"14583","DOI":"10.1073\/pnas.251543298","volume":"98","author":"M Oullet","year":"2001","unstructured":"Oullet, M., Riendeau, D. & Percival, M. D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl Acad. Sci. USA 98, 14583\u201314588 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro201197_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amepre.2004.03.008","volume":"27","author":"C Kim","year":"2004","unstructured":"Kim, C. & Beckles, G. L. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am. J. Prev. Med. 27, 1\u20137 (2004).","journal-title":"Am. J. Prev. Med."},{"key":"BFnrgastro201197_CR5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0025-7753(04)74155-X","volume":"122","author":"E Esmatjes","year":"2003","unstructured":"Esmatjes, E., Castell, C., Franch, J., Puigoriol, E. & Hernandez, R. Acetylsalicylic acid consumption in patients with diabetes mellitus [Spanish]. Med. Clin. (Barc.) 122, 96\u201398 (2003).","journal-title":"Med. Clin. (Barc.)"},{"key":"BFnrgastro201197_CR6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3181\/00379727-214-44087","volume":"214","author":"JL Wallace","year":"1997","unstructured":"Wallace, J. L. & Chin, B. C. Inflammatory mediators in gastrointestinal defense and injury. Proc. Soc. Exp. Biol. Med. 214, 192\u2013203 (1997).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrgastro201197_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.ph.47.030185.001245","volume":"47","author":"W Silen","year":"1985","unstructured":"Silen, W. & Ito, S. Mechanisms for rapid re-epithelialization of the gastric mucosal surface. Annu. Rev. Physiol. 47, 217\u2013229 (1985).","journal-title":"Annu. Rev. Physiol."},{"key":"BFnrgastro201197_CR8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/0016-5085(88)90667-1","volume":"94","author":"SJ Konturek","year":"1988","unstructured":"Konturek, S. J., Dembinski, A., Warzecha, Z., Brzozowski, T. & Gregory, H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 94, 1300\u20131307 (1988).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0928-4257(01)00046-8","volume":"95","author":"A Tarnawski","year":"2001","unstructured":"Tarnawski, A., Szabo, I. L., Husain, S. S. & Soreghan, B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J. Physiol. Paris 95, 337\u2013344 (2001).","journal-title":"J. Physiol. Paris"},{"key":"BFnrgastro201197_CR10","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1073\/pnas.111150798","volume":"98","author":"L Ma","year":"2001","unstructured":"Ma, L.  et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl Acad. Sci. USA 98, 6470\u20136475 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro201197_CR11","doi-asserted-by":"crossref","first-page":"PL1","DOI":"10.1016\/0024-3205(94)90083-3","volume":"55","author":"BK Reuter","year":"1994","unstructured":"Reuter, B. K., Cirino, G. & Wallace, J. L. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci. 55, PL1\u2013PL8 (1994).","journal-title":"Life Sci."},{"key":"BFnrgastro201197_CR12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/01.CIR.0000124715.27937.78","volume":"109","author":"ML Capone","year":"2004","unstructured":"Capone, M. L.  et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468\u20131471 (2004).","journal-title":"Circulation"},{"key":"BFnrgastro201197_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prostaglandins.2006.05.019","volume":"82","author":"ML Capone","year":"2007","unstructured":"Capone, M. L.  et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 82, 85\u201394 (2007).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"BFnrgastro201197_CR14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bcp.2003.09.020","volume":"67","author":"W Tomisato","year":"2004","unstructured":"Tomisato, W.  et al. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem. Pharmacol. 67, 575\u2013585 (2004).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrgastro201197_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0016-5085(19)33594-2","volume":"61","author":"DJ Hingson","year":"1971","unstructured":"Hingson, D. J. & Ito, S. Effect of aspirin and related compounds on the fine structure of mouse gastric mucosa. Gastroenterology 61, 156\u2013177 (1971).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0016-5085(70)80057-9","volume":"58","author":"MG Geall","year":"1970","unstructured":"Geall, M. G., Phillips, S. F. & Summerskill, W. H. Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acid. Gastroenterology 58, 437\u2013443 (1970).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-85-3-299","volume":"85","author":"WN Baskin","year":"1976","unstructured":"Baskin, W. N., Ivey, K. J., Krause, W. J., Jeffrey, G. E. & Gemmell, R. T. Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference. Ann. Intern. Med. 85, 299\u2013303 (1976).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro201197_CR18","first-page":"211","volume":"67","author":"JC O'Laughlin","year":"1981","unstructured":"O'Laughlin, J. C., Hoftiezer, J. W. & Ivey, K. J. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand. J. Gastroenterol. Suppl. 67, 211\u2013214 (1981).","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"BFnrgastro201197_CR19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","volume":"321","author":"S Derry","year":"2000","unstructured":"Derry, S. & Loke, Y. K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321, 1183\u20131187 (2000).","journal-title":"BMJ"},{"key":"BFnrgastro201197_CR20","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/S0002-9270(00)01040-6","volume":"95","author":"HT Sorensen","year":"2000","unstructured":"Sorensen, H. T.  et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am. J. Gastroenterol. 95, 2218\u20132224 (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro201197_CR21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","volume":"348","author":"JP Kelly","year":"1996","unstructured":"Kelly, J. P.  et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348, 1413\u20131416 (1996).","journal-title":"Lancet"},{"key":"BFnrgastro201197_CR22","first-page":"227","volume":"20","author":"A Chowdhury","year":"2001","unstructured":"Chowdhury, A.  et al. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J. Gastroenterol. 20, 227\u2013229 (2001).","journal-title":"Indian J. Gastroenterol."},{"key":"BFnrgastro201197_CR23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","volume":"52","author":"LA Garcia Rodriguez","year":"2001","unstructured":"Garcia Rodriguez, L. A., Hernandez-Diaz, S. & de Abajo, F. J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br. J. Clin. Pharmacol. 52, 563\u2013571 (2001).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrgastro201197_CR24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0006-2952(00)00576-1","volume":"61","author":"LM Lichtenberger","year":"2001","unstructured":"Lichtenberger, L. M. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol. 61, 631\u2013637 (2001).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrgastro201197_CR25","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0002-9343(99)00365-4","volume":"107","author":"KD Rainsford","year":"1999","unstructured":"Rainsford, K. D. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am. J. Med. 107, 27S\u201335S (1999).","journal-title":"Am. J. Med."},{"key":"BFnrgastro201197_CR26","first-page":"95","volume":"26","author":"I Bjarnason","year":"2007","unstructured":"Bjarnason, I., Scarpignato, C., Takeuchi, K. & Rainsford, K. D. Determinants of the short term gastric damage caused by NSAIDs in man. Aliment. Pharmacol. Ther. 26, 95\u2013106 (2007).","journal-title":"Pharmacol. Ther."},{"key":"BFnrgastro201197_CR27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.gastro.2004.04.003","volume":"127","author":"RL Darling","year":"2004","unstructured":"Darling, R. L.  et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 127, 94\u2013104 (2004).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0016-5085(85)80185-2","volume":"88","author":"LM Lichtenberger","year":"1985","unstructured":"Lichtenberger, L. M., Richards, J. E. & Hills, B. A. Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa. Gastroenterology 88, 308\u2013314 (1985).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/toxsci\/kfg045","volume":"73","author":"KW Oh","year":"2003","unstructured":"Oh, K. W., Qian, T., Brenner, D. A. & Lemasters, J. J. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol. Sci. 73, 44\u201352 (2003).","journal-title":"Toxicol. Sci."},{"issue":"Suppl. 1","key":"BFnrgastro201197_CR30","first-page":"A-341","volume":"134","author":"G Kamada","year":"2008","unstructured":"Kamada, G.  et al. Evaluation of gastric mucosal blood flow using contrast enhanced ultrasonography during low dose aspirin therapy and during NSAID and low dose aspirin combined therapy [abstract M1114]. Gastroenterology 134 (Suppl. 1), A-341 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10620-006-9553-y","volume":"52","author":"M Odashima","year":"2007","unstructured":"Odashima, M.  et al. Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phosphodiesterase in rats. Dig. Dis. Sci. 52, 1355\u20131359 (2007).","journal-title":"Dig. Dis. Sci."},{"key":"BFnrgastro201197_CR32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/ard.55.4.211","volume":"55","author":"T Mahmud","year":"1996","unstructured":"Mahmud, T., Scott, D. L. & Bjarnason, I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann. Rheum. Dis. 55, 211\u2013213 (1996).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 5","key":"BFnrgastro201197_CR33","first-page":"125","volume":"57","author":"PC Konturek","year":"2006","unstructured":"Konturek, P. C., Kania, J., Hahn, E. G. & Konturek, J. W. Ascorbic acid attenuates aspirin induced gastric damage: role of inducible nitric oxide synthase. J. Physiol. Pharmacol. 57 (Suppl. 5), 125\u2013136 (2006).","journal-title":"J. Physiol. Pharmacol."},{"key":"BFnrgastro201197_CR34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01213310","volume":"32","author":"NM Davies","year":"1997","unstructured":"Davies, N. M. & Wallace, J. L. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J. Gastroenterol. 32, 127\u2013133 (1997).","journal-title":"J. Gastroenterol."},{"key":"BFnrgastro201197_CR35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2008.12.019","volume":"7","author":"E Smecuol","year":"2009","unstructured":"Smecuol, E.  et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin. Gastroenterol. Hepatol. 7, 524\u2013529 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro201197_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","volume":"3","author":"JL Goldstein","year":"2005","unstructured":"Goldstein, J. L.  et al. Video capsule endoscopy to prospectively assesses small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. 3, 133\u2013141 (2005).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro201197_CR37","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.27412","volume":"62","author":"EL Mass\u00f3 Gonz\u00e1lez","year":"2010","unstructured":"Mass\u00f3 Gonz\u00e1lez, E. L., Patrignani, P., Tacconelli, S. & Rodr\u00edguez, L. A. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 62, 1592\u20131601 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrgastro201197_CR38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0928-4257(01)00005-5","volume":"95","author":"A Tanaka","year":"2001","unstructured":"Tanaka, A., Araki, H., Komoike, Y., Hase, S. & Takeuchi, K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 95, 21\u201327 (2001).","journal-title":"J. Physiol. Paris"},{"key":"BFnrgastro201197_CR39","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","volume":"297","author":"CL Campbell","year":"2007","unstructured":"Campbell, C. L., Smyth, S., Montalescot, G. & Steinhubl, S. R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297, 2018\u20132024 (2007).","journal-title":"JAMA"},{"key":"BFnrgastro201197_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0262-1746(82)90013-0","volume":"9","author":"MM Cohen","year":"1982","unstructured":"Cohen, M. M. & MacDonald, W. C. Mechanism of aspirin injury to human gastroduodenal mucosa. Prostaglandins Leukot. Med. 9, 241\u2013255 (1982).","journal-title":"Prostaglandins Leukot. Med."},{"key":"BFnrgastro201197_CR41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.1994.tb00319.x","volume":"8","author":"DL Hogan","year":"1994","unstructured":"Hogan, D. L., Ainsworth, M. A. & Isenberg, J. I. Review article: gastroduodenal bicarbonate secretion. Aliment. Pharmacol. Ther. 8, 475\u2013488 (1994).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201197_CR42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/00365528509095830","volume":"110","author":"C Johansson","year":"1985","unstructured":"Johansson, C., Aly, A., Befrits, R., Smedfors, B. & Uribe, A. Protection of the gastroduodenal mucosa by prostaglandins. Scand. J. Gastroenterol. Suppl. 110, 41\u201348 (1985).","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"BFnrgastro201197_CR43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2036.1999.00470.x","volume":"13","author":"AT Cole","year":"1999","unstructured":"Cole, A. T.  et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment. Pharmacol. Ther. 13, 187\u2013193 (1999).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201197_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1254\/jjp.37.91","volume":"37","author":"I Arai","year":"1985","unstructured":"Arai, I., Hirose, H., Muramatsu, M., Okuyama, S. & Aihara, H. Possible involvement of non-steroidal anti-inflammatory drugs in vagal-mediated gastric acid secretion in rats. Jpn J. Pharmacol. 37, 91\u201399 (1985).","journal-title":"Jpn J. Pharmacol."},{"key":"BFnrgastro201197_CR45","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3109\/00365528909090792","volume":"24","author":"E Jaramillo","year":"1989","unstructured":"Jaramillo, E.  et al. The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells. Scand. J. Gastroenterol. 24, 1231\u20131237 (1989).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro201197_CR46","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3109\/00365529209000162","volume":"27","author":"M Leivonen","year":"1992","unstructured":"Leivonen, M., Sipponen, P. & Kivilaakso, E. Gastric changes in coronary-operated patients with low-dose aspirin. Scand. J. Gastroenterol. 27, 912\u2013916 (1992).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro201197_CR47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10620-005-1281-1","volume":"50","author":"Y Niv","year":"2005","unstructured":"Niv, Y.  et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig. Dis. Sci. 50, 78\u201380 (2005).","journal-title":"Dig. Dis. Sci."},{"key":"BFnrgastro201197_CR48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","volume":"22","author":"ND Yeomans","year":"2005","unstructured":"Yeomans, N. D.  et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. 22, 795\u2013801 (2005).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201197_CR49","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.2174\/138161207781368837","volume":"13","author":"F Sopena","year":"2007","unstructured":"Sopena, F. & Lanas, A. How to advise aspirin use in patients who need NSAIDs. Curr. Pharm. Des. 13, 2248\u20132260 (2007).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrgastro201197_CR50","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","volume":"45","author":"ML Capone","year":"2005","unstructured":"Capone, M. L.  et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol. 45, 1295\u20131301 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrgastro201197_CR51","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono, C., Garcia Rodriguez, L. A., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373\u20132383 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"7329","key":"BFnrgastro201197_CR52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"A. T. Collaboration","year":"2002","unstructured":"Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71\u201386 (2002).","journal-title":"BMJ"},{"key":"BFnrgastro201197_CR53","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archneur.62.8.1217","volume":"62","author":"AB Maulaz","year":"2005","unstructured":"Maulaz, A. B., Bezerra, D. C. & Michel, P. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch. Neurol. 62, 1217\u20131220 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrgastro201197_CR54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjmed.2007.10.002","volume":"121","author":"JS Berger","year":"2008","unstructured":"Berger, J. S., Brown, D. L. & Becker, R. C. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am. J. Med. 121, 43\u201349 (2008).","journal-title":"Am. J. Med."},{"key":"BFnrgastro201197_CR55","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjmed.2005.11.013","volume":"119","author":"JE Dalen","year":"2006","unstructured":"Dalen, J. E. Aspirin to prevent heart attack and stroke: what's the right dose? Am. J. Med. 119, 198\u2013202 (2006).","journal-title":"Am. J. Med."},{"key":"BFnrgastro201197_CR56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.2010.507629","volume":"10","author":"A Lanas","year":"2011","unstructured":"Lanas, A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin. Drug Saf. 10, 45\u201354 (2011).","journal-title":"Expert Opin. Drug Saf."},{"key":"BFnrgastro201197_CR57","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent, C.  et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Antithrombotic Trialists' (ATT) Collaboration. Lancet 373, 1849\u20131860 (2009).","journal-title":"Lancet"},{"key":"BFnrgastro201197_CR58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","volume":"106","author":"PM Ridker","year":"2010","unstructured":"Ridker, P. M., MacFadyen, J., Libby, P. & Glynn, R. J. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol. 106, 204\u2013209 (2010).","journal-title":"Am. J. Cardiol."},{"key":"BFnrgastro201197_CR59","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/j.1572-0241.2008.01995.x","volume":"103","author":"N Yeomans","year":"2008","unstructured":"Yeomans, N.  et al. Efficacy of esomeprazole (20\u00a0mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol. 103, 2465\u20132473 (2008).","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"BFnrgastro201197_CR60","first-page":"A","volume":"136","author":"James M. Scheiman","year":"2009","unstructured":"Scheiman, J. M.  et al. Prevention of low-dose acetylsalicylic acidassociated gastric\/duodenal ulcers with esomeprazole 20\u00a0mg and 40\u00a0mg once daily in patients at increased risk of ulcer development: a randomized controlled trial (OBERON). Gastroenterology 136, A-70 (2009).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MAJ.0b013e3181ad8cd3","volume":"338","author":"A Lanas","year":"2009","unstructured":"Lanas, A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am. J. Med. Sci. 338, 96\u2013106 (2009).","journal-title":"Am. J. Med. Sci."},{"key":"BFnrgastro201197_CR62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","volume":"136","author":"M Hayden","year":"2002","unstructured":"Hayden, M., Pignone, M., Phillips, C. & Mulrow, C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 136, 161\u2013172 (2002).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro201197_CR63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","volume":"119","author":"KR McQuaid","year":"2006","unstructured":"McQuaid, K. R. & Laine, L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624\u2013638 (2006).","journal-title":"Am. J. Med."},{"key":"BFnrgastro201197_CR64","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","volume":"340","author":"S Juul-Moller","year":"1992","unstructured":"Juul-Moller, S.  et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 340, 1421\u20131425 (1992).","journal-title":"Lancet"},{"key":"BFnrgastro201197_CR65","doi-asserted-by":"crossref","unstructured":"The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75\u00a0mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338, 1345\u20131349 (1991).","DOI":"10.1016\/0140-6736(91)92233-R"},{"key":"BFnrgastro201197_CR66","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1572-0241.2005.41833.x","volume":"100","author":"A Lanas","year":"2005","unstructured":"Lanas, A.  et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol. 100, 1685\u20131693 (2005).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro201197_CR67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.mog.0000153314.51198.58","volume":"21","author":"PJ Fortun","year":"2005","unstructured":"Fortun, P. J. & Hawkey, C. J. Nonsteroidal antiinfl ammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 21, 169\u2013175 (2005).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"BFnrgastro201197_CR68","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/gut.27.11.1292","volume":"27","author":"I Bjarnason","year":"1986","unstructured":"Bjarnason, I., Williams, P., Smethurst, P., Peters, T. J. & Levi, A. J. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 27, 1292\u20131299 (1986).","journal-title":"Gut"},{"key":"BFnrgastro201197_CR69","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/0016-5085(92)91712-D","volume":"102","author":"I Bjarnason","year":"1992","unstructured":"Bjarnason, I.  et al. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 102, 1546\u20131550 (1992).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR70","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar2355","volume":"10","author":"RA Moore","year":"2008","unstructured":"Moore, R. A., Derry, S. & McQuay, H. J. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res. Ther. 10, R7 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrgastro201197_CR71","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/030079907X162656","volume":"23","author":"A Lanas","year":"2007","unstructured":"Lanas, A. & Scheiman, J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin. 23, 163\u2013173 (2007).","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnrgastro201197_CR72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7015-4-22","volume":"4","author":"S Hernandez-Diaz","year":"2006","unstructured":"Hernandez-Diaz, S. & Garcia Rodriguez, L. A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 4, 22 (2006).","journal-title":"BMC Med."},{"key":"BFnrgastro201197_CR73","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","volume":"52","author":"DL Bhatt","year":"2008","unstructured":"Bhatt, D. L.  et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF\/ACG\/AHA expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52, 1502\u20131517 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl. 6","key":"BFnrgastro201197_CR74","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","volume":"133","author":"RA Harrington","year":"2008","unstructured":"Harrington, R. A.  et al. American College of Chest Physicians. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (Suppl. 6), 670S\u2013707S (2008).","journal-title":"Chest"},{"key":"BFnrgastro201197_CR75","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329\u20131339 (1996).","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"BFnrgastro201197_CR76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2006.02759.x","volume":"23","author":"L Ib\u00e1\u00f1ez","year":"2006","unstructured":"Ib\u00e1\u00f1ez, L.  et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment. Pharmacol. Ther. 23, 235\u2013242 (2006).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201197_CR77","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","volume":"55","author":"A Lanas","year":"2006","unstructured":"Lanas, A.  et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 55, 1731\u20131738 (2006).","journal-title":"Gut"},{"key":"BFnrgastro201197_CR78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","volume":"352","author":"FK Chan","year":"2005","unstructured":"Chan, F. K.  et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352, 238\u2013244 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201197_CR79","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","volume":"102","author":"A Lanas","year":"2007","unstructured":"Lanas, A.  et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with NSAIDs and anti-platelet agents. Am. J. Gastroenterol. 102, 507\u2013515 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro201197_CR80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM200009213431202","volume":"343","author":"A Lanas","year":"2000","unstructured":"Lanas, A.  et al. Nitrovasodilators, low dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 343, 834\u2013839 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201197_CR81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(09)61246-0","volume":"374","author":"AS Taha","year":"2009","unstructured":"Taha, A. S., McCloskey, C., Prasad, R. & Bezlyak, V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374, 119\u2013125 (2009).","journal-title":"Lancet"},{"key":"BFnrgastro201197_CR82","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.3748\/wjg.v16.i42.5342","volume":"16","author":"H Nema","year":"2010","unstructured":"Nema, H. & Kato, M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J. Gastroenterol. 16, 5342\u20135346 (2010).","journal-title":"World J. Gastroenterol."},{"key":"BFnrgastro201197_CR83","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2009.09.063","volume":"138","author":"FH Ng","year":"2010","unstructured":"Ng, F. H.  et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138, 82\u201388 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR84","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","volume":"301","author":"PM Ho","year":"2009","unstructured":"Ho, P. M.  et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J. Am. Med. Assoc. 301, 937\u2013944 (2009).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnrgastro201197_CR85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ajg.2009.638","volume":"105","author":"L Laine","year":"2010","unstructured":"Laine, L. & Hennekens, C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol. 105, 34\u201341 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro201197_CR86","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","volume":"180","author":"DN Juurlink","year":"2009","unstructured":"Juurlink, D. N.  et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180, 713\u2013718 (2009).","journal-title":"CMAJ"},{"key":"BFnrgastro201197_CR87","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","volume":"51","author":"M Gilard","year":"2008","unstructured":"Gilard, M.  et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256\u2013260 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrgastro201197_CR88","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","volume":"101","author":"D Sibbing","year":"2009","unstructured":"Sibbing, D.  et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101, 714\u2013719 (2009).","journal-title":"Thromb. Haemost."},{"key":"BFnrgastro201197_CR89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","volume":"48","author":"DS Small","year":"2008","unstructured":"Small, D. S.  et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 48, 475\u2013484 (2008).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrgastro201197_CR90","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt, D. L.  et al. The COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363, 1909\u20131917 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201197_CR91","unstructured":"FDA Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) \n                    [online]\n                    \n                  , (2009)."},{"key":"BFnrgastro201197_CR92","unstructured":"EMEA Public statement on possible interaction between clopidogrel and proton pump inhibitors \n                    [online]\n                    \n                  , (2009)."},{"key":"BFnrgastro201197_CR93","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2036.2002.01230.x","volume":"16","author":"A Lanas","year":"2002","unstructured":"Lanas, A.  et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low dose aspirin. Aliment. Pharmacol. Ther. 16, 779\u2013786 (2002).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201197_CR94","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","volume":"344","author":"FK Chan","year":"2001","unstructured":"Chan, F. K.  et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967\u2013973 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201197_CR95","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa012877","volume":"346","author":"KC Lai","year":"2002","unstructured":"Lai, K. C.  et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346, 2033\u20132038 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201197_CR96","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2036.2010.04415.x","volume":"32","author":"EH Fletcher","year":"2010","unstructured":"Fletcher, E. H.  et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment. Pharmacol. Ther. 32, 831\u2013839 (2010).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro201197_CR97","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/07853890600925843","volume":"38","author":"A Lanas","year":"2006","unstructured":"Lanas, A. & Hunt, R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann. Med. 38, 415\u2013428 (2006).","journal-title":"Ann. Med."},{"key":"BFnrgastro201197_CR98","first-page":"943","volume":"6","author":"R Gao","year":"2010","unstructured":"Gao, R. & Li, X. Risk assessment and aspirin use in Asian and Western populations. Vasc. Health Risk Manag. 6, 943\u2013956 (2010).","journal-title":"Vasc. Health Risk Manag."},{"key":"BFnrgastro201197_CR99","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.medcli.2010.07.002","volume":"135","author":"A Lanas","year":"2010","unstructured":"Lanas, A.  et al. First Spanish consensus on peptic ulcer bleeding management. Consenso sobre Hemorragia Digestiva por \u00dalcera P\u00e9ptica [Spanish]. Med. Clin. (Barc.) 135, 608\u2013616 (2010).","journal-title":"Med. Clin. (Barc.)"},{"key":"BFnrgastro201197_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","volume":"152","author":"JY Sung","year":"2010","unstructured":"Sung, J. Y.  et al. Continuation of low dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 152, 1\u20139 (2010).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro201197_CR101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1034\/j.1600-079x.2002.1o811.x","volume":"32","author":"I Brzozowska","year":"2002","unstructured":"Brzozowska, I.  et al. Role of prostaglandins, nitric oxide, sensory nerves and gastrin in acceleration of ulcer healing by melatonin and its precursor, L-tryptophan. J. Pineal Res. 32, 149\u2013162 (2002).","journal-title":"J. Pineal Res."},{"issue":"Suppl. 5","key":"BFnrgastro201197_CR102","first-page":"51","volume":"57","author":"SJ Konturek","year":"2006","unstructured":"Konturek, S. J., Konturek, P. C. & Brzozowski, T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J. Physiol. Pharmacol. 57 (Suppl. 5), 51\u201366 (2006).","journal-title":"J. Physiol. Pharmacol."},{"key":"BFnrgastro201197_CR103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-079X.2010.00755.x","volume":"48","author":"PC Konturek","year":"2010","unstructured":"Konturek, P. C.  et al. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J. Pineal Res. 48, 318\u2013323 (2010).","journal-title":"J. Pineal Res."},{"key":"BFnrgastro201197_CR104","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11537380-000000000-00000","volume":"27","author":"A Pilotto","year":"2010","unstructured":"Pilotto, A., Franceschi, M., Maggi, S., Addante, F. & Sancarlo, D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging 27, 545\u2013558 (2010).","journal-title":"Drugs Aging"},{"key":"BFnrgastro201197_CR105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.gastro.2007.09.035","volume":"134","author":"AT Chan","year":"2008","unstructured":"Chan, A. T.  et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134, 21\u201328 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR106","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell, P. M.  et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741\u20131750 (2010).","journal-title":"Lancet"},{"key":"BFnrgastro201197_CR107","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","volume":"101","author":"BF Cole","year":"2009","unstructured":"Cole, B. F.  et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl Cancer Inst. 101, 256\u2013266 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrgastro201197_CR108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000047514","volume":"8","author":"BJ Meyer","year":"1998","unstructured":"Meyer, B. J. Antithrombotic drugs: insights from cardiology. Cerebrovasc. Dis. 8, 19\u201327 (1998).","journal-title":"Cerebrovasc. Dis."},{"key":"BFnrgastro201197_CR109","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1017\/CBO9780511545283.062","volume-title":"Platelets in thrombotic and non thrombotic disorders: pathophysiology, pharmacology and therapeutics","author":"C Patrono","year":"2002","unstructured":"Patrono, C. in Platelets in thrombotic and non thrombotic disorders: pathophysiology, pharmacology and therapeutics 919\u2013928 (Cambridge University Press, 2002)."},{"key":"BFnrgastro201197_CR110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","volume":"367","author":"GJ Hankey","year":"2006","unstructured":"Hankey, G. J. & Eikelboom, J. W. Aspirin resistance. Lancet 367, 606\u2013617 (2006).","journal-title":"Lancet"},{"key":"BFnrgastro201197_CR111","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/153537020122601107","volume":"226","author":"JL Wallace","year":"2001","unstructured":"Wallace, J. L. & Ma, L. Inflammatory mediators in gastrointestinal defence and injury. Exp. Biol. Med. (Maywood) 226, 1003\u20131015 (2001).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"BFnrgastro201197_CR112","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2000.9304","volume":"119","author":"JL Wallace","year":"2000","unstructured":"Wallace, J. L. & Miller, M. J. Nitric oxide in mucosal defence: A little goes a long way. Gastroenterology 119, 512\u2013520 (2000).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR113","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/gast.2003.50096","volume":"124","author":"S Fiorucci","year":"2003","unstructured":"Fiorucci, S.  et al. Gastrointestinal safety of NO-aspirin (NCX 4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124, 600\u2013607 (2003).","journal-title":"Gastroenterology"},{"key":"BFnrgastro201197_CR114","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/BF02065551","volume":"40","author":"PJ Goddard","year":"1995","unstructured":"Goddard, P. J. & Lichtenberger, L. M. In vitro recovery of canine gastric mucosal surface hydrophobicity and potential difference after aspirin damage. Dig. Dis. Sci. 40, 1357\u20131359 (1995).","journal-title":"Dig. Dis. Sci."},{"key":"BFnrgastro201197_CR115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ajg.2010.436","volume":"106","author":"B Cryer","year":"2011","unstructured":"Cryer, B.  et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am. J. Gastroenterol. 106, 272\u2013277 (2011).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro201197_CR116","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.freeradbiomed.2010.02.014","volume":"48","author":"D Giustarini","year":"2010","unstructured":"Giustarini, D., Del Soldato, P., Sparatore, A. & Rossi, R. Modulation of thiol homeostasis induced by H2S-releasing aspirin. Free Radic. Biol. Med. 48, 1263\u20131272 (2010).","journal-title":"Free Radic. Biol. Med."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2011.97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2011.97","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2011.97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:44:48Z","timestamp":1684467888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2011.97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFnrgastro201197"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2011.97","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}